share_log

KPC PharmaceuticalsInc's (SHSE:600422) Shareholders May Want To Dig Deeper Than Statutory Profit

KPC PharmaceuticalsInc's (SHSE:600422) Shareholders May Want To Dig Deeper Than Statutory Profit

KPC PharmaceticalsInc(上海證券交易所代碼:600422)的股東可能希望獲得比法定利潤更深入的挖掘
Simply Wall St ·  03/30 07:25

Following the solid earnings report from KPC Pharmaceuticals,Inc (SHSE:600422), the market responded by bidding up the stock price. However, we think that shareholders should be cautious as we found some worrying factors underlying the profit.

繼KPC Pharmicals, Inc (SHSE: 600422) 發佈穩健的收益報告之後,市場的回應是提高了股價。但是,我們認爲股東應謹慎行事,因爲我們發現了利潤背後的一些令人擔憂的因素。

earnings-and-revenue-history
SHSE:600422 Earnings and Revenue History March 29th 2024
SHSE: 600422 2024 年 3 月 29 日的收益和收入歷史記錄

How Do Unusual Items Influence Profit?

不尋常的物品如何影響利潤?

For anyone who wants to understand KPC PharmaceuticalsInc's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from CN¥74m worth of unusual items. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. Which is hardly surprising, given the name. If KPC PharmaceuticalsInc doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.

對於任何想了解KPC PharmaceuticalsInc在法定數字之外的利潤的人來說,值得注意的是,在過去的十二個月中,從價值7400萬元人民幣的不尋常物品中獲得了法定利潤。我們不能否認更高的利潤通常會讓我們感到樂觀,但如果利潤是可持續的,我們更願意這樣做。當我們分析全球絕大多數上市公司時,我們發現重大不尋常的事項往往不會重演。考慮到這個名字,這並不奇怪。如果KPC PharmaceuticalsInc認爲這種捐款不會重演,那麼在其他條件相同的情況下,我們預計其本年度的利潤將下降。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

這可能會讓你想知道分析師對未來盈利能力的預測。幸運的是,您可以單擊此處查看根據他們的估計描繪未來盈利能力的交互式圖表。

Our Take On KPC PharmaceuticalsInc's Profit Performance

我們對KPC PharmaceicalsInc盈利表現的看法

Arguably, KPC PharmaceuticalsInc's statutory earnings have been distorted by unusual items boosting profit. Therefore, it seems possible to us that KPC PharmaceuticalsInc's true underlying earnings power is actually less than its statutory profit. The good news is that, its earnings per share increased by 16% in the last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. If you'd like to know more about KPC PharmaceuticalsInc as a business, it's important to be aware of any risks it's facing. For example - KPC PharmaceuticalsInc has 1 warning sign we think you should be aware of.

可以說,提高利潤的不尋常項目扭曲了KPC PharmaceicalsInc的法定收益。因此,在我們看來,KPC PharmaceuticalsInc的真正潛在盈利能力實際上可能低於其法定利潤。好消息是,其每股收益在去年增長了16%。當然,我們只是在分析其收益時才浮出水面;人們還可以考慮利潤率、預測增長和投資回報率等因素。如果您想進一步了解KPC PharmaceuticalsInc作爲一家企業,請務必了解其面臨的任何風險。例如,KPC PharmaceuticalsInc 有 1 個我們認爲你應該注意的警告信號。

This note has only looked at a single factor that sheds light on the nature of KPC PharmaceuticalsInc's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

本報告僅研究了揭示KPC PharmaceuticalsInc利潤性質的單一因素。但是,還有很多其他方法可以讓你對公司的看法。有些人認爲高股本回報率是優質業務的好兆頭。因此,你可能希望看到這份免費收藏的擁有高股本回報率的公司,或者這份內部人士正在購買的股票清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論